NO940194D0 - Purification of recombinant cilitic neurotrophic factor and C-terminal truncated cilitic neurotrophic factor and methods of treating peripheral nerve damage - Google Patents

Purification of recombinant cilitic neurotrophic factor and C-terminal truncated cilitic neurotrophic factor and methods of treating peripheral nerve damage

Info

Publication number
NO940194D0
NO940194D0 NO940194A NO940194A NO940194D0 NO 940194 D0 NO940194 D0 NO 940194D0 NO 940194 A NO940194 A NO 940194A NO 940194 A NO940194 A NO 940194A NO 940194 D0 NO940194 D0 NO 940194D0
Authority
NO
Norway
Prior art keywords
neurotrophic factor
cilitic
purification
recombinant
methods
Prior art date
Application number
NO940194A
Other languages
Norwegian (no)
Inventor
Franklin D Collins
Deborah Russell
John R Mcdonald
Erwin Freund
Larry J Wilhelm
Duane Mach Bonam
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of NO940194D0 publication Critical patent/NO940194D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Fremgangsmåte for produksjon og rensing av rekombinant ciliær neurotrof faktor. Rensing av C-terminaltrunkerte former av ciliær neurotrof faktor ble også beskrevet. Fremgangsmåter for å hindre og behandle perifer nerveskade blir tilveiebrakt. Fremgangsmåten omfatter administrering til pasienter som har behov for dette en terapeutisk effektiv mengde av CN7TF. En foretrukket fremgangsmåte for å fremstille CNTF er ved rekombinant DNA-teknologi.Method for production and purification of recombinant ciliary neurotrophic factor. Purification of C-terminal truncated forms of ciliary neurotrophic factor was also described. Methods for preventing and treating peripheral nerve damage are provided. The method comprises administering to patients in need thereof a therapeutically effective amount of CN7TF. A preferred method of producing CNTF is by recombinant DNA technology.

NO940194A 1991-07-23 1994-01-19 Purification of recombinant cilitic neurotrophic factor and C-terminal truncated cilitic neurotrophic factor and methods of treating peripheral nerve damage NO940194D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73553891A 1991-07-23 1991-07-23
US75317691A 1991-08-30 1991-08-30
PCT/US1992/006136 WO1993002206A1 (en) 1991-07-23 1992-07-21 Purification of recombinant ciliary neurotrophic factor and c-terminal truncated ciliary neurotrophic factor and methods for treating peripheral nerve damage

Publications (1)

Publication Number Publication Date
NO940194D0 true NO940194D0 (en) 1994-01-19

Family

ID=27112907

Family Applications (2)

Application Number Title Priority Date Filing Date
NO949194A NO940194L (en) 1991-07-23 1994-01-19 Purification of recombinant ciliary neurotrophic factor by C-terminal truncated ciliary neurotrophic factor and procedures for treating peripheral nerve damage
NO940194A NO940194D0 (en) 1991-07-23 1994-01-19 Purification of recombinant cilitic neurotrophic factor and C-terminal truncated cilitic neurotrophic factor and methods of treating peripheral nerve damage

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO949194A NO940194L (en) 1991-07-23 1994-01-19 Purification of recombinant ciliary neurotrophic factor by C-terminal truncated ciliary neurotrophic factor and procedures for treating peripheral nerve damage

Country Status (12)

Country Link
EP (1) EP0596034A4 (en)
JP (1) JPH07500725A (en)
AU (1) AU666327B2 (en)
CA (1) CA2113815A1 (en)
FI (1) FI940302A0 (en)
HU (1) HUT67352A (en)
IE (1) IE922402A1 (en)
IL (1) IL102607A0 (en)
MX (1) MXPA92004329A (en)
NO (2) NO940194L (en)
NZ (1) NZ243691A (en)
WO (1) WO1993002206A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
IT1288388B1 (en) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio USE OF SUBSTANCES THAT ACTIVATE THE CNTF RECEPTOR (NEUROTROPHIC CHILI FACTOR) FOR THE PREPARATION OF DRUGS FOR THERAPY
EP1013280A4 (en) * 1998-06-10 2004-04-28 Bml Inc Skin preparations for external use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US501914A (en) * 1893-07-25 Method of building engine-foundations
US5011914A (en) * 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
EP0463082A1 (en) * 1989-03-15 1992-01-02 The Regents Of The University Of California Purified ciliary neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
HUT62033A (en) * 1990-03-14 1993-03-29 Fidia Spa Process for producing human ciliary body neuronotropic factor
AU2925392A (en) * 1991-11-11 1993-06-15 Fidia S.P.A. Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor

Also Published As

Publication number Publication date
AU666327B2 (en) 1996-02-08
NZ243691A (en) 1995-12-21
HUT67352A (en) 1995-03-28
WO1993002206A1 (en) 1993-02-04
HU9400133D0 (en) 1994-05-30
MXPA92004329A (en) 2005-04-01
FI940302A (en) 1994-01-21
CA2113815A1 (en) 1993-02-04
EP0596034A1 (en) 1994-05-11
FI940302A0 (en) 1994-01-21
EP0596034A4 (en) 1995-05-24
IE922402A1 (en) 1993-01-27
JPH07500725A (en) 1995-01-26
IL102607A0 (en) 1993-01-14
NO940194L (en) 1994-02-08
AU2443292A (en) 1993-02-23

Similar Documents

Publication Publication Date Title
ATE255635T1 (en) POLYPEPTIDE CAPABLE OF INHIBITING THE BINDING BETWEEN HUMAN IL-6 AND ITS RECEPTOR
NO914714D0 (en) THERAPEUTIC USEFUL 2-AMINOTETRALIN DERIVATIVES
ATE82507T1 (en) MEDICAL USE.
IE873157L (en) Controlled absorption ismn containing formulations
NO932610L (en) PROCEDURE FOR TREATMENT OF TUMOR CANCER FACTOR CONCERNED DISEASES
BR9709068A (en) Treatment process.
DE69731540D1 (en) TREATMENT OF DIARRHOE
NO20065027L (en) Process for Preparation of a Biologically Active, Recombinant Human Human Coagulation Factor VIII in a Cell Culture Medium Allowing Expression and Secretion of the Polypeptide
DE69730330D1 (en) USE OF L-ACETYLCARNITIN, L-ISOVALERYLCARNITIN OR L-PROPIONYL-CARNITIN TO INCREASE IGF MIRROR
DE69418601T2 (en) GUANID DERIVATIVES WITH THERAPEUTIC EFFECT
ES2105766T3 (en) LEVOBUPIVACAINE USED IN THE TREATMENT OF CHRONIC PAIN.
NO169346C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 17BETA (CYCLOPROPYLAMINO) ANDROST-5-EN-3BETA OLS AND RELATED COMPOUNDS
NO940194D0 (en) Purification of recombinant cilitic neurotrophic factor and C-terminal truncated cilitic neurotrophic factor and methods of treating peripheral nerve damage
ATE149840T1 (en) TREATMENT OF LIVER CANCER
NO944714L (en) Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders
NO952904L (en) Lysine salt of 6-chloro-5-fluoro-3- (2-tenoyl) -2-oxindole-1-carboxamide
UA28379A (en) Method for treatment by transdermal medications
Cho Continuing Education/Psychiatric Nursing-Nursing care for psychiatric patients
RU93037848A (en) METHOD OF TREATMENT OF LEPROI PATIENTS
AU7931487A (en) Therapeutic treatment of abnormal cell growth with follicle regulatory protein
RU93046326A (en) METHOD OF TREATMENT OF MEDICAMENTAL EZOPHAGO-GINGOVO-STOMATITIS
RU96121507A (en) METHOD OF INFERTILITY TREATMENT IN MEN
ZA925465B (en) Purification of recombinant ciliary neurotrophic factor and C-terminal truncated ciliary neurothropic factor and methods for treating peripheral nerve damage
UA22223A (en) Method for treatment of vision organ diseases
RU94028941A (en) Method for treating peptic ulcer disease